SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
103,600
+6,100 (6.26%)
Last updated: Jul 17, 2025
26.65%
Market Cap7.64T
Revenue (ttm)578.00B
Net Income (ttm)251.21B
Shares Out78.31M
EPS (ttm)3,207.77
PE Ratio30.39
Forward PE45.30
Dividendn/a
Ex-Dividend Daten/a
Volume494,031
Average Volume183,507
Open98,400
Previous Close97,500
Day's Range98,100 - 104,400
52-Week Range72,600 - 130,000
Beta0.86
RSI57.95
Earnings DateAug 8, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 241
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.